Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. is a phase 2 interventional study registered as NCT05201066 by Novartis Pharmaceuticals, with 33 participants enrolled, started 2023-02-28 and due to reach its primary completion in 2028-02-14. Interventions recorded: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax and INQOVI (oral decitabine).